key: cord-0022230-qesnq5in
authors: Thivolet, Pr Charles
title: Insulin pump initiation in outpatient settings: when technology facilitates new healthcare organizations
date: 2021-10-18
journal: Diabetes Metab
DOI: 10.1016/j.diabet.2021.101290
sha: 1184e446224fd12595e8d4b036571aa029980c48
doc_id: 22230
cord_uid: qesnq5in

nan

Diabetes-related technology has undergone many changes in recent years, both in the fields of continuous glucose measurement and insulin administration. This technology uptake has been delivered for years by specialized centers and the numbers of persons with diabetes (PwD) treated with an insulin pump has increased with time. Automated insulin delivery systems are the most recent advancement in diabetes technology, with algorithms allowing automatic insulin delivery based on sensor-glucose levels [1] . Despite the benefits associated with the use of diabetes technology, ongoing barriers exist and include: i) personal concerns including attachment to a device in real-life conditions and constraints for physical activity; ii) patient and family expectations toward hospitalization for initiating pump therapy; iii) lack of resources for healthcare providers and difficulties for caregivers to maintain experience with the devices so they can provide the necessary education and support. With such a critical role, diabetes care facilities must have an appropriately available well-educated and experienced staff. The adoption of lockdown measures in 2020 to restrain the spread of SARS-CoV-2 infection leading to limited access to outpatient and inpatient clinics has seriously challenged our models of care and impacted access to pump therapy. The subsequent restrictions of day-to-day life and hospital visits accelerated the telehealth transition in many countries including France, with the development of remote diabetes monitoring. Insulin pump initiation in outpatient settings actively challenges current healthcare organizations. For more than 20 years, inpatient initiation has been required in France for health insurance beneficiaries to get full healthcare coverage that includes revenue for both the initiating center and the healthcare providers who ensure on-call follow-up and supply for home-care patients [2]. To maintain outpatient care programs and 24-hour health provider availability for assistance, it is necessary to adapt our care facilities and to develop specialized diabetes centers. Faced with growing challenges in terms of material and human resources, it is important not to give in to demand or to transfer skills to service providers or manufacturers, but rather to rethink our healthcare organizations. Centers dedicated to type 1 diabetes providing comprehensive and individualized care for children and adults that were launched 15 years ago by two pediatricians in The Netherlands (https://diabeter.nl/en/aboutdiabeter/who-we-are/) were bought six years ago by an insulin pump manufacturer. In Lyon, France, we had the opportunity to open a specialized center named DIAB-eCARE (www.diab-ecare.fr), dedicated to care for adolescents and adults with type 1 diabetes. DIAB-eCARE uses exclusive hospital resources to propose an alternative model for outpatients with full-cost insurance coverage [3] . With adapted education programs and telehealth monitoring, this model of care has several advantages including: i) care delivery for PwD in their natural surroundings which reduces the barriers inhibiting access to technology through ambulatory education programs; ii) frequent interactions between PwD and care providers; iii) reduction of the economic burden in contrast to inpatient pump initiation. This natural evolution of healthcare organizations needs to be consolidated by specific fundings to reduce barriers related to socioeconomic disparities and financial constraints. The capacity to develop remote care through interoperative platforms facilitates interactions between PwD and the healthcare team to optimize diabetes control and to reduce the overall burden of technology. It is therefore urgent to integrate funded healthcare professional time for the uptake of and initiation and adherence to these new devices. With this ability to provide easy access to diabetes technology and provider education, we can expect an overall improvement in care for people with type 1 diabetes.

New closed-loop insulin systems